drugset / Trial / NCT00830791

A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

NCT00830791

Phase 1 Terminated 32 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the pharmacokinetics of MK-0941 in participants with varying degrees of renal insufficiency.

Timeline

Start
2009-01
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0941 Small molecule 5 mg Oral
Subject MK-0941 Small molecule 20 mg Oral